Lupus Nephritis research hub

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

This study is looking at a new medicine called obinutuzumab for teenagers and children aged 5 to 17 with a kidney condition called lupus nephritis. We want to see if it's safe, how well it works, and how the body uses it.

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

This study is testing a new cell therapy called rapcabtagene autoleucel for severe lupus (SLE) or lupus affecting the kidneys (lupus nephritis). It aims to see how well it works and if it's safe for people whose current treatments aren't effective.

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

This study is looking at a new medicine called obinutuzumab for people with a serious kidney problem called lupus nephritis. Researchers want to see if it's safe and helps better than a dummy medicine when added to usual treatments, like steroids.

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

This study is looking at a new medicine called iptacopan for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see how well it works and if it's safe when added to standard treatments.

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

This study looks at a new treatment called obe-cel for severe lupus affecting the kidneys (lupus nephritis). It's for people aged 12-65 whose current treatments haven't worked. The aim is to see if obe-cel can make their kidney lupus go into remission.

A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)